AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost entirely from the US market and before the contribution from Europe was ...

AbbVie Inc. ABBV reported first-quarter 2025 adjusted earnings per share (EPS) of $2.46, which beat the Zacks Consensus ...

AbbVie's takeover of ImmunoGen was driven by expectations of big sales for Elahere, and GlobalData recently predicted that, with its first-to-market advantage, the ADC could generate $2.8 billion ...

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience ...